SCHEMBL8693335

SCHEMBL8693335

CC(=NO)C(C)(C)NCCCNC(C)(C)C(C)=NO

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.37
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8693325 1.00 POLB (0.37) POLBTSHRSMN1; SMN2
Upenazime SCHEMBL1477985 0.95 POLB (0.37) POLBTSHRSMN1; SMN2
SCHEMBL15144439 0.93 POLB (0.36) POLBTSHRSMN1; SMN2
SCHEMBL15135657 0.93 POLB (0.36) POLBTSHRSMN1; SMN2
SCHEMBL7118056 0.92 POLB (0.33) POLB
SCHEMBL7118054 0.92 POLB (0.33) POLB
SCHEMBL26537222 0.89 POLB (0.34) POLBTSHR
SCHEMBL7121165 0.88 POLB (0.35) POLB
SCHEMBL8362134 0.87 POLB (0.33) POLBTSHR
SCHEMBL8362130 0.87 POLB (0.33) POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019418-A1 SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES OHIO STATE INNOVATION FOUNDATION 2025-01-16 US disclosed
CN-111225679-B Novel peptide-based cancer imaging agents 俄亥俄州创新基金会 2024-03-29 CN disclosed
US-20230338584-A1 NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS OHIO STATE INNOVATION FOUNDATION 2023-10-26 US disclosed
WO-2023086152-A1 SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES OHIO STATE INNOVATION FOUNDATION (US) 2023-05-19 WO disclosed
US-11419951-B2 Peptide-based cancer imaging agents OHIO STATE INNOVATION FOUNDATION (US) 2022-08-23 US disclosed
US-20220218834-A1 APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-14 US disclosed
US-11358982-B2 Methods for the iodination of biomolecules OHIO STATE INNOVATION FOUNDATION (US) 2022-06-14 US disclosed
EP-3972646-A1 APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF Ohio State Innovation Foundation (US) 2022-03-30 EP disclosed
US-5776894-A Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors NOVARTIS AG (CH) 1998-07-07 US disclosed
US-5753627-A Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis NOVARTIS AG (CH) 1998-05-19 US disclosed
EP-0515313-A2 Somatostatin analogues containing chelating groups and their radiolabeled compositions SANDOZ LTD. (CH) 1992-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019418-A1 SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES MB, HMBS, HCCS POLB 1439/4885TSHR 1966/4885SMN1; SMN2 1093/4885
US-11358982-B2 Methods for the iodination of biomolecules TPO, LPO, MPO POLB 1053/4885TSHR 100/4885SMN1; SMN2 4273/4885
US-20220218834-A1 APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF HBG1, HBG2, LPO POLB 1274/4885TSHR 4182/4885SMN1; SMN2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.